1.Sackett, DL (1969) Clinical epidemiology. Am J Epidemiol 89, 125–128.
2.Desai, S, lsmail, SJ, Lerch, R, Warshawsky, BF, Gemmill, I (2015) Canada's National Advisory Committee on Immunization: Celebrating 50 years. Can J Infect Dis Med Microbiol 26, 126–128.
3.No Authors listed (1979) The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 121, 1193–1254.
4.Battista, RN, Côté, B, Hodge, MJ, Husereau, D (2009) Health technology assessment in Canada. Int J Technol Assess Health Care 25(Suppl 1), 53–60.
5.Martin, J, Polisena, J, Dendukuri, N, Rhainds, M, Sampietro-Colom, L (2016) Local health technology assessment in Canada: Current state and next steps. Int J Technol Assess Health Care 32, 175–180.
6.Sackett, DL, Rosenberg, WMC, Gray, JAM, Haynes, RB, Richardson, WS (1996) Evidence based medicine: What it is and what it isn't. BMJ 312, 71–72.
7.Rocchi, A, Miller, E, Hopkins, RB, Goeree, R (2012) common drug review recommendations: An evidence base for expectations? PharmacoEconomics 30, 229–246.
8.Panteli, D, Arickx, F, Cleemput, I, et al. (2016) Pharmaceutical regulation in 15 European countries review. Health Syst Transit 18, 1–122.
9.Royle, P, Kandala, N-B, Barnard, K, Waugh, N (2013) Bibliometrics of systematic reviews: Analysis of citation rates and journal impact factors. Syst Rev 2, 74.
10.Jamali, A, Nedjat, S, Heidari, K, et al. (2015) Worldwide inequality in production of systematic reviews. Med J Islam Repub Iran 29, 309.
11.Rocchi, A, Menon, D, Verma, S, Miller, E (2008) The role of economic evidence in Canadian oncology reimbursement decision-making: To lambda and beyond. Value Health 11, 771–783.
12.Jacobs, P, Roos, NP (1999) Standard cost lists for healthcare in Canada. Issues in validity and inter-provincial consolidation. PharmacoEconomics 15, 551–560.
13.Roos, NP, Black, C, Frohlich, N, et al. (1996) Population health and health care use: An information system for policy makers. Milbank Q 74, 3–31.
14.Fisher, ES, Malenka, DJ, Wennberg, JE, Roos, NP (1990) Technology assessment using insurance claims. Example of prostatectomy. Int J Technol Assess Health Care 6, 194–202.
15.Klemp, M, Frønsdal, KB, Facey, K, HTAi Policy Forum (2011) What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care 27, 77–83.
16.Lucyk, K, Lu, M, Sajobi, T, Quan, H (2015) Administrative health data in Canada: Lessons from history. BMC Med Inform Decis Mak 15, 69.
17.Morin, SN, Flegel, K (2017) A national health care data network is overdue. CMAJ 189, E951.
22.Scott, PJ, Rigby, M, Ammenwerth, E, et al. (2017) Evaluation considerations for secondary uses of clinical data: Principles for an evidence-based approach to policy and implementation of secondary analysis. A position paper from the IMIA Technology Assessment & Quality Development in Health Informatics Working Group. Yearb Med Inform 26, 59–67.
23.Council of Canadian Academies (2015) Accessing health and health-related data in Canada: The expert panel on timely access to health and social data for health research and health system innovation. Ontario: Council of CanadianAcademies.
24.Garrison, LP, Neumann, PJ, Erickson, P, Marshall, D, Mullins, CD (2007) Using real-world data for coverage and payment decisions: The ISPOR Real-World Data Task Force report. Value Health 10, 326–335.
25.McCabe, CJ, Stafinski, T, Edlin, R, Menon, D (2010) Access with evidence development schemes: A framework for description and evaluation. PharmacoEconomics 28, 143–152.
27.Elshaug, AG, Moss, JR, Littlejohns, P, et al. (2009) Identifying existing health care services that do not provide value for money. Med J Aust 190, 269–273.
31.Kalkman, S, van Thiel, G, Zuidgeest, MGP, Goetz, I (2017) Challenges of informed consent for pragmatic trials. J Clin Epidemiol doi:10.1016/j.jclinepi.2017.03.019
32.Kim, SYH, Miller, FG (2014) Informed consent for pragmatic trials--the integrated consent model. N Engl J Med 370, 769–772.
33.Campbell, D (1969) Reforms as experiments. Am Psychol 24, 409–429.
35.Ivers, NM, Grimshaw, JM (2016) Reducing research waste with implementation laboratories. Lancet 388, 547–548.
42.Suissa, S, Henry, D, Caetano, P, et al. (2012) CNODES: The Canadian Network for Observational Drug Effect Studies. Open Med 6, e134–e140.
43.Birtwhistle, R, Keshavjee, K, Lambert-Lanning, A, et al. (2009) Building a pan-Canadian primary care sentinel surveillance network: Initial development and moving forward. J Am Board Fam Med 22, 412–422.
44.Hennessy, DA, Flanagan, WM, Tanuseputro, P, et al. (2015) The Population Health Model (POHEM): An overview of rationale, methods and applications. Popul Health Metr 13, 24.
45.Canadian Centre for Applied Research in Cancer Control. About Canadian Centre for Applied Research in Cancer Control. https://cc-arcc.ca/.
47.Collier, R (2011) Federal government unveils patient-oriented research strategy. CMAJ 183, E993–E994.
50.Khan, S, Moore, JE, Gomes, T, et al. (2014) The Ontario Drug Policy Research Network: Bridging the gap between research and drug policy. Health Policy 117, 392–398.
51.Dolan, D, Grainger, J, MacCallum, N, et al. (2012) The Institute for Clinical Evaluative Sciences: 20 years and counting. Healthc Q 15, 19–21.
52.Roos, NP, Roos, LL, Freemantle, J (2011) Administrative data and the Manitoba Centre for Health Policy: Some reflections. Healthc Policy 6, 16–28.
53.Chamberlayne, R, Green, B, Barer, ML, et al. (1998) Creating a population-based linked health database: A new resource for health services research. Can J Public Health 89, 270–273.